The Food and Drug Administration approved Novo Nordisk 's weight-loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in people with obesity and heart disease. Millions of patients already use the injectable treatment, but the agency's decision could widen insurance coverage for the drug and similar treatments for obesity. The approval also demonstrates that weight loss drugs have significant health benefits beyond shedding unwanted pounds and regulating blood sugar.